

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2023 January 15; 15(1): 1-214



## Contents

Monthly Volume 15 Number 1 January 15, 2023

## REVIEW

- 1 Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma  
*Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT*
- 19 Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma  
*Lai HC, Lin HJ, Jeng LB, Huang ST*
- 36 Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review  
*Zhong YL, Wang PQ, Hao DL, Sui F, Zhang FB, Li B*
- 55 Challenges and exploration for immunotherapies targeting cold colorectal cancer  
*Li DD, Tang YL, Wang X*

## MINIREVIEWS

- 69 Research progress of integrated traditional Chinese and Western medicine in the treatment of advanced gastric cancer  
*Ye HN, Liu XY, Qin BL*

## ORIGINAL ARTICLE

## Basic Study

- 76 Hsa\_circ\_0001658 accelerates the progression of colorectal cancer through miR-590-5p/METTL3 regulatory axis  
*Lu Y, Wang XM, Li ZS, Wu AJ, Cheng WX*

## Clinical and Translational Research

- 90 Network pharmacology-based analysis of heat clearing and detoxifying drug JC724 on the treatment of colorectal cancer  
*Tang HZ, Yang ZP, Lu S, Wang B, Wang YY, Sun XB, Qu JX, Rao BQ*

## Case Control Study

- 102 Diagnostic accuracy of the multi-target stool DNA test in detecting colorectal cancer: A hospital-based study  
*Gao HL, Lv LB, Zhao WF, Lu QW, Fan JQ*

## Retrospective Study

- 112 Development and validation of a nomogram for predicting metachronous peritoneal metastasis in colorectal cancer: A retrospective study  
*Ban B, Shang A, Shi J*

- 128** Risk factors, prognostic predictors, and nomograms for pancreatic cancer patients with initially diagnosed synchronous liver metastasis  
*Cao BY, Tong F, Zhang LT, Kang YX, Wu CC, Wang QQ, Yang W, Wang J*
- 143** Short-term efficacy and influencing factors of conventional chemotherapy combined with irinotecan in patients with advanced gastric cancer  
*Wang JP, Du JL, Li YY*
- 155** Survival benefits and disparities in radiation therapy for elderly patients with pancreatic ductal adenocarcinoma  
*Cao BY, Wang QQ, Zhang LT, Wu CC, Tong F, Yang W, Wang J*

### META-ANALYSIS

- 171** Rs3746444 T>C locus in miR-499 increases the susceptibility to hepatocellular carcinoma: A meta-analysis 14812 subjects  
*Jiang JK, Chen HS, Tang WF, Chen Y, Lin J*

### CASE REPORT

- 186** Local recurrence after successful endoscopic submucosal dissection for rectal mucinous mucosal adenocarcinoma: A case report  
*Murakami Y, Tanabe H, Ono Y, Sugiyama Y, Kobayashi Y, Kunogi T, Sasaki T, Takahashi K, Ando K, Ueno N, Kashima S, Yuzawa S, Moriichi K, Mizukami Y, Fujiya M, Okumura T*
- 195** Intestinal natural killer/T-cell lymphoma presenting as a pancreatic head space-occupying lesion: A case report  
*Wang YN, Zhu YM, Lei XJ, Chen Y, Ni WM, Fu ZW, Pan WS*
- 205** Surgical treatments of recurrent small intestine metastatic melanoma manifesting with gastrointestinal hemorrhage and intussusception: A case report  
*Fan WJ, Cheng HH, Wei W*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Jing He, PhD, Research Fellow, Department of Pediatric Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong Province, China. hejing198374@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

**INDEXING/ABSTRACTING**

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJGO as 3.404; IF without journal self cites: 3.357; 5-year IF: 3.250; Journal Citation Indicator: 0.53; Ranking: 162 among 245 journals in oncology; Quartile category: Q3; Ranking: 59 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Gastroenterology is 72/149; Oncology is 203/360.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Xiang-Di Zhang; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

January 15, 2023

**COPYRIGHT**

© 2023 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Research progress of integrated traditional Chinese and Western medicine in the treatment of advanced gastric cancer

Hui-Nan Ye, Xiao-Yan Liu, Bao-Li Qin

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Mitsunashi N, Japan;  
Zaanan A, France

**Received:** September 28, 2022

**Peer-review started:** September 28, 2022

**First decision:** October 21, 2022

**Revised:** October 28, 2022

**Accepted:** December 21, 2022

**Article in press:** December 21, 2022

**Published online:** January 15, 2023



Hui-Nan Ye, Xiao-Yan Liu, Bao-Li Qin, Department of Gastroenterology, Cancer Hospital of China Medical University; Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital & Institute, Shenyang 110801, Liaoning Province, China

**Corresponding author:** Bao-Li Qin, PhD, Chief Doctor, Department of Gastroenterology, Cancer Hospital of China Medical University; Cancer Hospital of Dalian University of Technology; Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyuan Road, Dadong District, Shenyang 110801, Liaoning Province, China. [poryqin@126.com](mailto:poryqin@126.com)

### Abstract

Gastric cancer (GC) is a malignant tumor originating from the gastric epithelium, and its incidence and mortality rates rank third among all malignant tumors worldwide. It is also one of the most common cancers in China and is treated predominantly by Western medicine in clinical practice. However, with the advancements in medical technology and informatics, the values of traditional Chinese medicine (TCM) in preventing and treating GC and improving prognosis have increasingly been recognized. According to TCM, clinical manifestations of GC can be divided into Yege (dysphagia), regurgitation, stomach pain, and Zhengxia (abdominal mass). Due to the unbalanced distribution of health care resources in China, most GC patients already have progressive or advanced-stage disease at the first diagnosis. As a result, most GC patients have poor physical function, and surgery or chemotherapy alone will aggravate the impairment to the immune function and seriously affect the quality of life. In contrast, TCM therapies have shown promising efficacy in the management of these patients. Here we review the role of the integrated TCM and Western medicine in treating advanced GC.

**Key Words:** Integrated traditional Chinese medicine and Western medicine; Advanced gastric cancer; Research advances

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The incidence and mortality rates of gastric cancer (GC) rank third among all malignant tumors worldwide. In recent years, traditional Chinese medicine (TCM) has been increasingly applied in the clinical treatment of GC. The integrated TCM and the modern medicine can, to a certain extent, improve the therapeutic effects and reduce the adverse reactions caused by the modern medication in cancer treatment.

**Citation:** Ye HN, Liu XY, Qin BL. Research progress of integrated traditional Chinese and Western medicine in the treatment of advanced gastric cancer. *World J Gastrointest Oncol* 2023; 15(1): 69-75

**URL:** <https://www.wjgnet.com/1948-5204/full/v15/i1/69.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v15.i1.69>

## INTRODUCTION

According to the global cancer burden data released by the International Agency for Research on Cancer, there will be 19.29 million new cancer cases and about 9.96 million deaths from cancer worldwide in 2020, including new cases (about 1.09 million) and deaths (about 770000) from gastric cancer; there will be about 4.57 million new cancer cases and 3 million deaths in China, including new cases (about 480000) and deaths (about 370000) from gastric cancer. (about 370000 cases)[1]. Advanced gastric cancer is a common clinical malignancy of the digestive system, with up to 90% of patients already having advanced gastric cancer at the time of initial consultation, and the 5-year survival rate for patients with distant metastases is less than 10%[2,3]. At present, Western medicine is frequently used for clinical treatment of advanced GC, in which, however, radiotherapy and/or chemotherapy are predominantly selected, and surgery is performed in selected patients, with unsatisfactory efficacy in general. As a result, more tumor patients now choose integrated traditional Chinese and Western medicine (ITCWM) for the treatment of their diseases with the wider use of traditional Chinese medicine (TCM) in clinical practice. Here we review the role of the ITCWM in treating advanced GC.

## PATHOGENESIS OF ADVANCED GC

According to the TCM principle, "Where evils converge, the qi must be deficient". Thus, the occurrence of tumors is the result of the decline of bodily functions. Phlegm-dampness, qi stagnation, blood stasis, and toxins due to spleen deficiency are the major causes of GC[4-6]. Regarding phlegm-dampness, Wei *et al*[7] proposed a theoretical assumption named the "Mushroom-Tumor-Phlegm microenvironment Theory", which explains the possibility of tumor recurrence after GC surgery due to the existence of a phlegm microenvironment in the remnant stomach. Cao *et al*[8] also pointed out that the internal retention of phlegm-turbidity is the pathogenesis of GC. From the perspective of Western medicine, the occurrence and development of GC are attributed to a variety of factors, including heredity, environment, and dietary habits such as high-salt diet, *Helicobacter pylori* infection, smoking, and alcoholism[9,10].

## TCM THERAPIES

Modern medicine has developed rapidly, and most patients choose to eliminate their gastrointestinal tumors by chemotherapy, surgery, and other methods. However, the risk of recurrence and metastasis still exists due to the persistence of mutagenic (carcinogenic) factors in the body and tumor immune escape[11]. The clinical application of TCM drugs, especially spleen-invigorating drugs, can block the effects of carcinogens on normal cells, kill cells with high metastatic potential, inhibit tumor metastasis, and thus exert a good inhibitory effect on tumors[12]. Jiabin Qiu, a well-known TCM oncologist in China, proposed that spleen-invigorating drug-based TCM prescriptions are superior to chemotherapy alone in the treatment of advanced GC. He found in a clinical trial that the TCM-treated group had improved immune markers (*e.g.*, E-RFC), hemoglobin level, and red blood cell count as well as decreased erythrocyte sedimentation rate and  $\alpha$ 1-AG level; and TCM treatment enhanced the immunity and improved the immune status[13]. Zhao *et al*[14] found that the spleen-invigorating Chinese herbal formula Weichangan (WCA) compound had an inhibitory effect on GC cell line SGC-7901 *in vivo*. WCA can induce apoptosis of GC cells and inhibit the proliferation of GC cells, thus suppressing the growth of SGC-7901 tumor xenografts in nude mice[9]. In addition, Yang *et al*[15] also conducted a research on the TCM classic formula Sijunzi Decoction, and found that this decoction could induce tumor cell apoptosis. Wang *et al*[16] demonstrated that the TCM formula Fuzheng Kangai Granule could inhibit



GC cells, especially for MKN-45 cells. Experiments have shown that the drug has a more significant effect on poorly-differentiated MKN-45 cancer cells than on well-differentiated MKN-28 cells and moderately-differentiated SGC-7901 GC cells. The drug can cause structural changes in cancer cells.

## WESTERN MEDICINE THERAPIES

Chemotherapy is a commonly used clinical treatment for GC. Studies have shown that, compared with GC patients who do not receive any treatment, chemotherapy could prolong the median survival by 7-8 mo in patients treated with chemotherapy[17]. Although patient survival is prolonged, the quality of life is decreased due to the poor immune function of the patients. In recent years, more targeted drugs (*e.g.*, apatinib and ramucirumab) have also been used in clinical practice, all of which have the VEGFR-2 inhibiting effect. Among them, apatinib is the most widely used, but with obvious adverse reactions such as fatigue, diarrhea, hypertension, and proteinuria[18]. Surgery is also a commonly used treatment for GC. In developed countries, laparoscopic surgery is commonly used due to the high proportion of early-stage GC. In China, however, most GC cases are diagnosed too late, resulting in a high incidence of advanced GC. Therefore, laparoscopic surgery for advanced GC has become a research hotspot in China in recent years[19,20]. During the pandemic of COVID-19, digestive endoscopy was proved to be a safe technique for the diagnosis and treatment of gastrointestinal diseases[21]. However, the operation requires high physical performance of the patients, and most patients will suffer from spleen-stomach weakness after surgery. Therefore, it has been proposed by Chinese authors that ITCWM can be used to treat advanced GC as it can achieve good anti-cancer effects while maintaining and improving the overall physical function[22].

## ITCWM

Some scholars emphasized two aspects in the treatment of advanced GC: (1) Using Western medicine to eliminate cancer lesions; and (2) using TCM to enhance the patient's immunity[23,24], so as to achieve the purpose of improving the quality of life. Wei *et al*[25] developed the prescription Jinlongshe Oral Liquid and used it in combination with chemotherapy to treat GC patients; they concluded that, compared with chemotherapy alone, TCM plus chemotherapy showed more prominent efficacy in treating advanced GC. GC-related complications (*e.g.*, gastrointestinal bleeding) can also be managed by ITCWM, with a high success rate[26]. Gastrointestinal complications such as bowel obstruction are common in patients with advanced GC. According to the TCM concept of "treatment based on syndrome differentiation", the route of drug administration may be changed: in addition to oral administration, the drugs may be also administered by instillation through anal canal, so as to promote the intestinal mucosal absorption of the drugs and increase local drug concentration. As a result, the intestinal obstruction can be effectively relieved[27]. The application of integrated traditional Chinese and Western medicine in the treatment of advanced gastric cancer is divided into four aspects (Figure 1).

### TCM-assisted surgery

While surgery is the mainstay of treatment for most GCs, most patients will suffer from spleen and stomach weakness and insufficient qi and blood after an invasive surgery. TCM therapies can strengthen the spleen and benefit qi, improve these symptoms, and reduce postoperative adverse reactions. Yu *et al*[28] divided 59 patients into observation group and control group. The control group received only the conventional nutrition support after surgery, and the observation group received nutrition support added with Sijunzi Decoction, which is composed of Tangshen, Atractylodes, Poria, and Licorice. It was found that the levels of T cells and immunoglobulin G (IgG) in the Sijunzi Decoction group were significantly increased on the 10<sup>th</sup> postoperative day ( $P < 0.05$ ). Thus, Sijunzi Decoction, a TCM prescription for strengthening the spleen and nourishing qi, can correct malnutrition in GC patients after surgery and improve humoral and cellular immune functions. Previously, Yu *et al*[29] and Peng *et al*[30] compared the plasma total protein, albumin, and gastrointestinal function recovery among GC patients receiving different postoperative nutritional support and reached a similar conclusion that the use of a TCM prescription (Qihuang No. 1) in the early postoperative period could promote gastrointestinal motility, stimulate the recovery of digestive function, and improve the body's cellular and immune functions, thereby exerting an inhibitory effect on tumors. In 2020, Zhang *et al*[31] used Huangqi Jianzhong Decoction in postoperative patients and compared its efficacy with that by conventional treatment in terms of gastrointestinal function recovery time, total TCM symptom score, patient albumin level, and health and economic indicators. The differences in these four indicators were all statistically significant. The Huangqi Jianzhong Decoction group recovered faster in gastrointestinal function, had a higher total TCM symptom score and a higher level of albumin on the fifth postoperative day, and it was more economical with lower hospitalization expenses[31].




Figure 1 Application of integrated traditional Chinese and western medicine in the treatment of advanced gastric cancer.

### TCM-assisted chemotherapy

For modern medicine, chemotherapy is a major treatment for most cancers, especially GC. From the perspective of TCM, however, chemotherapy for cancer is a method of "fighting poison with poison", which produces major toxicities, leading to qi and blood deficiencies in spleen and stomach and even affecting liver, kidney, and bone marrow. Therefore, many researchers have tried to integrate TCM therapies with chemotherapy as TCM can invigorate the blood and qi, strengthen the spleen and stomach, and nourish the liver and kidney, thus alleviating the toxicities and side effects of chemotherapy[32]. The selection of treatment methods for patients with advanced gastric cancer must be based on the patient's physical condition, disease severity, and disease stage. The combination of traditional Chinese and Western medicine adds Chinese medicine for boosting immunity to the chemotherapy regimen, which can improve the patient's immune function, inhibit cancer cells, and enhance the anti-cancer ability, and the curative effect is more significant[33]. Li *et al*[34] analyzed the data of 205 patients who were treated during the period from 2001 to 2018. Compared with the control group (use of conventional chemotherapy drugs), the TCM group (adding heterophyllus falsestarwort root, fried *Atractylodes*, *Poria*, and immature tangerine peel based on the drugs used in the control group) had significantly longer median survival (21.271 mo *vs* 10.849 mo,  $P = 0.001$ ) without adverse reactions related to TCM treatment. Thus, the safety and tolerance of the TCM therapy were good. The authors concluded that spleen-strengthening TCM combined with oxaliplatin and fluorouracil could improve the long-term survival in patients with advanced GC. Pan *et al*[35] also demonstrated that adding TCM prescriptions during chemotherapy significantly improved the overall survival and quality of life in GC patients. Li *et al*[36] believe that the main purpose of chemotherapy for advanced gastric cancer is to relieve symptoms, but due to many adverse reactions, and traditional Chinese medicine can alleviate these negative symptoms, it is necessary to treat advanced gastric cancer with integrated traditional Chinese and Western medicine. In the process of treatment, the application of traditional Chinese medicine should be as early as possible, and increasing "stomach qi" is the key to anti-cancer, because traditional medicine believes that "with a share of stomach qi, there is a share of vitality". Wang *et al*[37] treated the syndrome of qi and blood deficiency in elderly patients with advanced GC using Biejia Huajian Decoction combined with Tegafur (S-1). Compared with the control group (S-1 capsules alone), the combination group had significantly better efficacy. For patients with advanced GC, the combined therapy achieved a good short-term therapeutic effect, delayed disease progression, and improved the quality of life. In addition, it had a protective effect on leukocytes and gastrointestinal tract in patients with qi-blood deficiency caused by the advanced GC, thus reducing the treatment-related toxicities. The combinations of surgery, chemotherapy, and TCM therapy may also be valuable. Postoperative patients have weakened disease resistance, which will be further decreased after the use of postoperative chemotherapy. The TCM therapies for supporting the vital qi and eliminating evils, when used in combination with chemotherapy, can significantly improve the body's immunity and reduce the chemotherapy-related toxicities while effectively fighting against tumors[38].



### TCM-assisted interventional therapy

Due to the scarcity of medical resources in China, most of the GC patients are diagnosed in the advanced stages, and surgery can cause severe damage to the patients. In recent years, with the advances in medical technology, interventional therapy is increasingly accepted by physicians and patients as a less invasive technique with fewer side effects[39]. The role of TCM in interventional therapy has been explored. In 2010, Xu *et al*[40] confirmed that, compared with interventional chemotherapy (oxaliplatin, 5-fluorouracil, and epirubicin) alone, the supplementation with Shenqi Jianzhong Decoction (which is composed of Tangshen, coix seed, Atractylodes, Zedaira rhizome, cassia twig, debark peony root, Salvia chinensis Benth, garden balsam seed, and Radix Glycyrrhizae) significantly improved the Karnofsky performance score and quality of life and relieved abdominal distension, anorexia, fatigue, stomach pain, and other symptoms ( $P < 0.05$ ); in addition, the combination reduced toxic and side effects and prevented postoperative tumor recurrence. During the hepatic artery interventional therapy for liver metastases from GC, the combination with Sijunzi Decoction could improve immune function, promote gastrointestinal motility, reduce adverse reactions, and improve the quality of life[41].

### TCM-assisted molecularly-targeted therapies

Molecularly-targeted therapy (MTT) has developed rapidly in recent years and has become an important treatment option for many tumors. By binding to the specific targets of tumor cells, MTT drugs can control apoptosis of tumor cells[42]. Apatinib is a commonly used MTT drug for the treatment of GC; however, it has many adverse effects such as hypertension, proteinuria, skin damage, blood toxicity, and gastrointestinal reactions. Tiaowei Hexue Decoction could enhance the anti-tumor effect of apatinib and meanwhile alleviate the above-mentioned adverse reactions[43], highlighting the advantage of TCM therapies in removing toxicities. In addition, apatinib can also be combined with Chaihu Guizhi Ganjiang Decoction in the treatment of advanced GC. Compared with apatinib monotherapy, the combined treatments significantly improved the clinical symptoms and reduced the incidence of adverse reactions, thus improving the physical status and quality of life of GC patients[44]. In 2014, Wilke *et al*[45] found that ramucirumab combined with paclitaxel prolonged survival in patients with advanced GC, providing strong evidence for the combination of TCM therapies with targeted therapy.

## CONCLUSION

The past decades have witnessed major progress in the treatment of cancers using surgery, chemotherapy, radiotherapy, MTT, immunotherapy, and other methods. However, each single therapy has its limitations and is associated with many adverse reactions. In recent years, with the tremendous efforts in the popularization of TCM in China, TCM has increasingly been applied in clinical settings. The combinations of TCM therapies with the modern treatments can, to a certain extent, improve the therapeutic effects and reduce the adverse reactions caused by modern medical technology. However, there is still a lack of understanding of TCM, and the value of ITCWM in the treatment of GC needs to be further explored in large-scale clinical trials.

## FOOTNOTES

**Author contributions:** Ye HN and Liu XY contributed equally to this work; Ye HN, Liu XY and Qin BL designed the study; Ye HN and Liu XY acquired the data; Ye HN and Liu XY analyzed and interpreted the data; Ye HN and Liu XY wrote the paper; Qin BL critically revised the manuscript for important intellectual content; all authors have read and approved the final version to be published.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Bao-Li Qin 0000-0003-2090-8721.

**S-Editor:** Gong ZM

**L-Editor:** A

P-Editor: Gong ZM

## REFERENCES

- 1 **International Agency for Research on Cancer.** Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. 2020 Available from: <https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/>
- 2 **Wagner AD,** Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev* 2017; **8**: CD004064 [PMID: 28850174 DOI: 10.1002/14651858.CD004064.pub4]
- 3 **Wang W,** Zheng C, Fang C, Li P, Xie J, Lin J, Zhan Y, Li W, Chen Y, Sun X, Xu D, Li Y, Huang C, Zhou Z. Time trends of clinicopathologic features and surgical treatment for gastric cancer: Results from 2 high-volume institutions in southern China. *Surgery* 2015; **158**: 1590-1597 [PMID: 26210225 DOI: 10.1016/j.surg.2015.04.038]
- 4 **Song Z,** Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. *Tumour Biol* 2017; **39**: 1010428317714626 [PMID: 28671042 DOI: 10.1177/1010428317714626]
- 5 **Huang LP,** Yu D, Li H, Yang JK. A brief discussion on Professor Yang Jinkun's clinical experience in the treatment of gastric cancer. *Zhejiang Zhongyiyao Daxue Xuebao* 2017; **41**: 747-751 [DOI: 10.16466/j.issn1005-5509.2017.09.010]
- 6 **Zhao AG,** Yang JK, Zheng J, Shen KP, Han YY, Gu Y, Zhou H, Zhu YJ. A study on the correlation between spleen deficiency and the occurrence and development of gastric cancer. *Shanghai Zhongyiyao Zazhi* 1998; **5**: 10-12 [DOI: 10.16305/j.1007-1334.1998.05.005]
- 7 **Wei PK,** Xu L, Sun DZ, Shi J, Qin ZF, Lu Y. The relationship between sputum and the development of gastric cancer. *Zhongyi Zazhi* 2006; **47**: 166-168 [DOI: 10.13288/j.11-2166/r.2006.03.002]
- 8 **Cao ND,** Zhao AG, Yang JK. Survival analysis of advanced gastric cancer in the treatment of integrated traditional Chinese and Western medicine. *J Integr Med* 2010; **8**: 116-120 [DOI: 10.3736/jcim20100204]
- 9 **Chan WC,** Millwood IY, Kartsonaki C, Du H, Guo Y, Chen Y, Bian Z, Walters RG, Lv J, He P, Hu C, Li L, Yang L, Chen Z; China Kadoorie Biobank (CKB) Collaborative Group. Spicy food consumption and risk of gastrointestinal-tract cancers: findings from the China Kadoorie Biobank. *Int J Epidemiol* 2021; **50**: 199-211 [PMID: 33484129 DOI: 10.1093/ije/dyaa275]
- 10 **Wang T,** Cai H, Sasazuki S, Tsugane S, Zheng W, Cho ER, Jee SH, Michel A, Pawlita M, Xiang YB, Gao YT, Shu XO, You WC, Epplein M. Fruit and vegetable consumption, Helicobacter pylori antibodies, and gastric cancer risk: A pooled analysis of prospective studies in China, Japan, and Korea. *Int J Cancer* 2017; **140**: 591-599 [PMID: 27759938 DOI: 10.1002/ijc.30477]
- 11 **Xu J,** Zhang J, Wang J. The Application of Traditional Chinese Medicine Against the Tumor Immune Escape. *J Transl Int Med* 2020; **8**: 203-204 [PMID: 33511046 DOI: 10.2478/jtim-2020-0032]
- 12 **Zhao Y,** Wang XW, Lu Y, Liu X, Xiu LJ, Yue XQ, Wei PK. The effect of traditional Chinese medicine syndrome differentiation treatment based on Xiaotan Sanjie formula on the quality of life in advanced gastric cancer. *Dier Junyi Daxue Xuebao* 2016; **37**: 1333-1337 [DOI: 10.16781/j.0258-879x.2016.11.1333]
- 13 **Qiu JX,** Jia JS, Yang JK, Zheng J, Zheng JC, Tang LD, Wang N, Shen KP, Pang HF, Ji GR, Qin DP, Li YM, Zhou XY, Luo XX, Liu MS, Qiu ZF, Cao LH, Dong MZ. Discussion on spleen strengthening method for the treatment of advanced gastric cancer. *Zhongyi Zazhi* 1992; **8**: 23-25 [DOI: 10.13288/j.11-2166/r.1992.08.018]
- 14 **Zhao AG,** Yang JK, You SF, Li T, Zhao HL, Gu Y, Tang LD. Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA. *Zhongguo Zhong Yao Za Zhi* 2007; **32**: 2028-2036 [PMID: 18161298]
- 15 **Qian J,** Li J, Jia J, Jin X, Yu D, Guo C, Xie B, Qian L. Different concentrations of Sijunzi decoction inhibit proliferation and induce apoptosis of human gastric cancer SGC-7901 side population. *Afr J Tradit Complement Altern Med* 2016; **13**: 145-156 [PMID: 28852730 DOI: 10.21010/ajtcam.v13i4.19]
- 16 **Xue G,** Liu J, Xu LJ, Shi J, Ling BF. Effects of Fuzheng Xiaoji Capsule on the proliferation inhibition and apoptosis of gastric cancer cells BGC-823. *Shijie Zhongyiyao* 2021; **16**: 1526-1529,1533 [DOI: 10.3969/j.issn.1673-7202.2021.10.005]
- 17 **Liu H,** Shi J. Research progress in the treatment of advanced gastric cancer. *Xiandai Zhongliu Yixue* 2021; **29**: 4226-4229 [DOI: 10.3969/j.issn.1672-4992.2021.23.035]
- 18 **Professional Committee on Clinical Research of Oncology Drugs;** Chinese Anti-Cancer Association; Expert Committee for Monitoring the Clinical Application of Antitumor Drugs; Breast Cancer Expert Committee of National Cancer Quality Control Center; Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center. [Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2020 Edition)]. *Zhonghua Zhong Liu Za Zhi* 2021; **43**: 78-91 [PMID: 33472318 DOI: 10.3760/cma.j.cn112152-20201112-00981]
- 19 **Xu ZK,** Wang LJ, Li BW. Progress and prospect of laparoscopic gastric cancer surgery. *Zhongguo Shiyong Waike Zaizhi* 2020; **40**: 185-190 [DOI: 10.19538/j.cjps.issn1005-2208.2020.02.11]
- 20 **Zhang Y,** Zhang B, Wang Y, Zhang J, Wu Y, Xiao T, Liao Y, Bao Y, Qiu H, Sun S, Guo J. Advances in the Prevention and Treatment of Esophageal Stricture after Endoscopic Submucosal Dissection of Early Esophageal Cancer. *J Transl Int Med* 2020; **8**: 135-145 [PMID: 33062589 DOI: 10.2478/jtim-2020-0022]
- 21 **Huang K,** Zhao X, Chen X, Gao Y, Yu J, Wu L. Analysis of Digestive Endoscopic Results During COVID-19. *J Transl Int Med* 2021; **9**: 38-42 [PMID: 33850800 DOI: 10.2478/jtim-2021-0006]
- 22 **Liu X,** Xiu LJ, Jiao JP, Zhao J, Zhao Y, Lu Y, Shi J, Li YJ, Ye M, Gu YF, Wang XW, Xu JY, Zhang CA, Liu YY, Luo Y, Yue XQ. Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: a retrospective clinical analysis. *J Integr Med* 2017; **15**: 469-475 [PMID: 29103417 DOI: 10.1016/S2095-4964(17)60377-7]
- 23 **Zhang LP,** Wang SH, Zhu J, Zhang YF. Clinical observation of 30 cases of advanced gastric cancer with yin deficiency syndrome treated by adjuvant chemotherapy with nourishing yin and sanitizing. *Hunan Zhongyi Zazhi* 2021; **37**: 8-12 [DOI: 10.16305/j.1007-1334.2021.01.008]

- 10.16808/j.cnki.issn1003-7705.2021.09.003]
- 24 **Wu ZX**, Wang Y, Li XJ, Qin ZS, He YT, Hou L. To explore the prognostic factors of advanced gastric cancer based on 80 patients with advanced gastric cancer who received integrated traditional Chinese and Western medicine. *Beijing Zhongyiyao* 2021; **40**: 876-879 [DOI: [10.16025/j.1674-1307.2021.08.022](https://doi.org/10.16025/j.1674-1307.2021.08.022)]
  - 25 **Yue XQ**, Wei PK. The practice of integrated traditional Chinese and Western medicine in the treatment of gastric cancer from the perspective of "phlegm". *Dier Junyi Daxue Xuebao* 2018; **39**: 1297-1301 [DOI: [10.16781/j.0258-879x.2018.12.1297](https://doi.org/10.16781/j.0258-879x.2018.12.1297)]
  - 26 **Shu P**, Tang H, Zhou B, Wang R, Xu Y, Shao J, Qi M, Xia Y, Huang W, Liu S. Effect of Yiqi Huayu Jiedu decoction on stages II and III gastric cancer: A multicenter, prospective, cohort study. *Medicine (Baltimore)* 2019; **98**: e17875 [PMID: [31764782](https://pubmed.ncbi.nlm.nih.gov/31764782/) DOI: [10.1097/MD.00000000000017875](https://doi.org/10.1097/MD.00000000000017875)]
  - 27 **Liang C**, Zheng LP, Deng HY, Liu D, Zhang YJ, Wu XF, Yuan JH. Observation on the curative effect of traditional Chinese medicine enema formula in the treatment of cancerous intestinal obstruction. *Shanxi Zhongyi* 2017; **33**: 54-55 [DOI: [10.3969/j.issn.1000-7156.2017.04.031](https://doi.org/10.3969/j.issn.1000-7156.2017.04.031)]
  - 28 **Yu XK**, Ren P. Effects of modified Sijunzi decoction combined with enteral nutrition on immune function in patients after gastric cancer surgery. *Zhongyi Xuebao* 2019; **34**: 621-624 [DOI: [10.16368/j.issn.1674-8999.2019.03.146](https://doi.org/10.16368/j.issn.1674-8999.2019.03.146)]
  - 29 **Yu QS**, Zhang FZ, Tang XR, Wang XJ, Fang XP. Effect of intra-intestinal drip of Astragalus I on the recovery of gastrointestinal function in the early postoperative period. *Zhongguo Zhongxiyi Jiehe Zazhi* 1994; **7**: 423
  - 30 **Peng H**, Yu QS, Zheng Z, Wang LY, Zhang Q, Zhou FH. Study on the effect of Qihuang decoction on intestinal motor function in rats after gastrectomy based on enteric nervous system. *Zhonghua Zhongyiyao Zazhi* 2021; **36**: 7279-7283
  - 31 **Zhang Y**, Gong HJ, Han G, Cao Y, Zhang YY, Zhang X. Clinical efficacy of Huangqi Jianzhong Tang in accelerating recovery of patients undergoing laparoscopic distal gastric cancer surgery. *Zhongguo Zhongyiyao Keji* 2020; **27**: 247-249
  - 32 **Yao Y**, Jia YJ, Deng RF, Zuo JH, Xie HX, Liao DY, Kong FM. Discussion on TCM staging, differentiation and treatment of myelosuppression caused by chemotherapy for gastric cancer. *Zhongyi Zhongliuxue Zazhi* 2020; **2**: 45-49 [DOI: [10.19811/j.cnki.ISSN2096-6628.2020.05.009](https://doi.org/10.19811/j.cnki.ISSN2096-6628.2020.05.009)]
  - 33 **Li JJ**, Liu XY. Research progress of traditional Chinese medicine in the treatment of advanced gastric cancer in the past five years. *Hebei Zhongyi* 2020; **42**: 312-316 [DOI: [10.3969/j.issn.1002-2619.2020.02.033](https://doi.org/10.3969/j.issn.1002-2619.2020.02.033)]
  - 34 **Li CY**, Zhao AG, Xu Y, Zhu XH, Cao ND, Zhao G, Guo WJ, Liu LK. Effect of spleen traditional Chinese medicine combined with Oplatin and fluorouracil chemotherapy on prognosis of patients with advanced gastric cancer. *Modern Tradit Chin Med Materia Medica-World Sc Technol* 2019; **21**: 1372-1377
  - 35 **Pan X**, Tao H, Nie M, Liu Y, Huang P, Liu S, Sun W, Wu J, Ma T, Dai A, Lu J, Liu B, Zou X, Sun Q. A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail. *Medicine (Baltimore)* 2020; **99**: e19757 [PMID: [32311976](https://pubmed.ncbi.nlm.nih.gov/32311976/) DOI: [10.1097/MD.00000000000019757](https://doi.org/10.1097/MD.00000000000019757)]
  - 36 **Li Y**, Li J. Buyang Yiwei Decoction combined with SOX chemotherapy regimen in the treatment of advanced gastric cancer. *Jinlin Zhongyiyao* 2021; **41**: 197-200 [DOI: [10.13463/j.cnki.jlzyy.2021.02.018](https://doi.org/10.13463/j.cnki.jlzyy.2021.02.018)]
  - 37 **Wang JM**. Clinical observation on the combination of turtle nail Hua Jian Tang with Tegeo in the treatment of advanced gastric cancer in the elderly with evidence of deficiency of both qi and blood. Hebin: Heilongjiang University of Traditional Chinese Medicine, 2014
  - 38 **Zhu XH**, Xu W, Zhao QF, Zhao AG, Zhao G, Guo WJ, Xu Y, Cao ND. Prospective concurrent controlled study of strengthening spleen-based traditional Chinese medicine compound combined with chemotherapy to prolong the survival of patients with advanced gastric cancer after retreatment. *Zhonghua Zhongyiyao Xuekan* 2018; **36**: 1844-1848 [DOI: [10.13193/j.issn.1673-7717.2018.08.013](https://doi.org/10.13193/j.issn.1673-7717.2018.08.013)]
  - 39 **Zhang W**, Zhao Y, Liu H, Jing C. Efficacy of Traditional Chinese Medicine Combined with Chemotherapy in the Treatment of Gastric Cancer: A Meta-analysis. *Comput Math Methods Med* 2022; **2022**: 8497084 [PMID: [35966237](https://pubmed.ncbi.nlm.nih.gov/35966237/) DOI: [10.1155/2022/8497084](https://doi.org/10.1155/2022/8497084)]
  - 40 **Xu Y**, Zhu LD. Ginseng Jianzhong Soup combined with arterial intervention in the treatment of 28 cases of gastric cancer in clinical research. *Jiangsu Zhongyiyao* 2010; **42**: 24-25 [DOI: [10.3969/j.issn.1672-397X.2010.05.014](https://doi.org/10.3969/j.issn.1672-397X.2010.05.014)]
  - 41 **Qiao SJ**, He LN. Efficacy evaluation of interventional therapy combined with traditional Chinese medicine in the treatment of liver metastasis of gastric cancer. *Shanxi Yiyao Zazhi* 2015; **44**: 181-182
  - 42 **Krajewski KM**, Braschi-Amirfarzan M, DiPiro PJ, Jagannathan JP, Shinagare AB. Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities. *Korean J Radiol* 2017; **18**: 28-41 [PMID: [28096716](https://pubmed.ncbi.nlm.nih.gov/28096716/) DOI: [10.3348/kjr.2017.18.1.28](https://doi.org/10.3348/kjr.2017.18.1.28)]
  - 43 **Ding MQ**, Liang H, Wu HH, Xu B. Clinical observation of gastric and blood soup combined with apatinib in the treatment of advanced gastric cancer. *Zhongguo Zhongxiyi Jiehe Zazhi* 2018; **38**: 1440-1443 [DOI: [10.7661/j.cjim.20181025.311](https://doi.org/10.7661/j.cjim.20181025.311)]
  - 44 **Li MY**. Clinical observation on the treatment of advanced gastric cancer with Chai Hu Gui Zhi Gan Jiang Tang Plus formula combined with Apatinib. Hebei North College, 2020 [DOI: [10.27767/d.cnki.ghbbf.2020.000056](https://doi.org/10.27767/d.cnki.ghbbf.2020.000056)]
  - 45 **Wilke H**, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014; **15**: 1224-1235 [PMID: [25240821](https://pubmed.ncbi.nlm.nih.gov/25240821/) DOI: [10.1016/S1470-2045\(14\)70420-6](https://doi.org/10.1016/S1470-2045(14)70420-6)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

